Main Field(s) of Research, Abstract
Acute myeloid leukaemia (AML) is a highly heterogeneous, clonal, malignant disease. It is characterised by a large increase in the number of immature cells in the blood and bone marrow. Although 70% of acute myeloid leukaemia (AML) patients achieve remission with standard chemotherapy regimens, 90% will relapse within 5 years. AML also represents about 3% of cancer deaths worldwide.
The rapid diagnosis of AML and the optimisation of a chemotherapeutic strategy is an important determinant of patient outcome. A new approach for determining the sensitivities of leukaemias to chemotherapeutics is proposed. Fluorescent analogues of current drugs, combined with specific antibody markers, will be used to generate multi-dimensional "fingerprints" of cell populations and their metabolism. Leukaemia cells collected from patients over the last 15 years will also be profiled. We hope to build correlations between the cellular fingerprint, chemotherapeutic regimen, and outcome in order to predict the best available treatment option for new AML patients.
Main Fields of Research, Keywords
Acute myeloid leukaemia, biomarker profiling, DNA damage, DNA repair, cell cycle, ex vivo
Special techniques and Equipment
Confocal microscopy, imaging flow cytometry